Open access · CC-BY
via OpenAlex
Epigenetic dysregulation in cardiovascular aging and disease
Allison B. Herman, James R. Occean, Payel Sen
The Journal of Cardiovascular Aging · 2021 · ▲ 40 citations
Epigenetic alterations
Cellular senescence
Chronic inflammation
Partial reprogramming (OSK)
Human
Mouse
Review
Abstract
Cardiovascular disease (CVD) is the leading cause of mortality and morbidity for all sexes, racial and ethnic groups. Age, and its associated physiological and pathological consequences, exacerbate CVD incidence and progression, while modulation of biological age with interventions track with cardiovascular health. Despite the strong link between aging and CVD, surprisingly few studies have directly investigated heart failure and vascular dysfunction in aged models and subjects. Nevertheless, strong correlations have been found between heart disease, atherosclerosis, hypertension, fibrosis, and regeneration efficiency with senescent cell burden and its proinflammatory sequelae. In agreement, senotherapeutics have had success in reducing the detrimental effects in experimental models of cardiovascular aging and disease. Aside from senotherapeutics, cellular reprogramming strategies targeting epigenetic enzymes remain an unexplored yet viable option for reversing or delaying CVD. Epigenetic alterations comprising local and global changes in DNA and histone modifications, transcription factor binding, disorganization of the nuclear lamina, and misfolding of the genome are telomere(definition) attrition, cellular senescence(definition))." style="text-decoration:underline dotted; text-underline-offset:2px; cursor:help;">hallmarks of aging(definition). Limited studies in the aging cardiovascular system of murine models or human patient samples have identified strong correlations between the epigenome, age, and senescence. Here, we compile the findings in published studies linking epigenetic changes to CVD and identify clear themes of epigenetic deregulation during aging. Pending direct investigation of these general mechanisms in aged tissues, this review predicts that future work will establish epigenetic rejuvenation as a potent method to delay CVD.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- OpenAlex
- DOI
- 10.20517/jca.2021.16
- Canonical
- link ↗
- Fetched
- 2026-08-25 MST
Cite this
APA
Herman, A.B., Occean, J.R., & Sen, P. (2021). Epigenetic dysregulation in cardiovascular aging and disease. <em>The Journal of Cardiovascular Aging</em>. https://doi.org/10.20517/jca.2021.16
Vancouver
Herman AB, Occean JR, Sen P. Epigenetic dysregulation in cardiovascular aging and disease. The Journal of Cardiovascular Aging. 2021. doi:10.20517/jca.2021.16.
BibTeX
@article{allison2021Epigen,
title = {Epigenetic dysregulation in cardiovascular aging and disease},
author = {Allison B. Herman and James R. Occean and Payel Sen},
journal = {The Journal of Cardiovascular Aging},
year = {2021},
doi = {10.20517/jca.2021.16},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Research Square 2026
Preprint · CC-BY
AI-driven biological clocks of cardiac aging: Should we integrate ECG, metabolomic, and epigenetic signatures?
Springer eBooks 2009
Citation only
Epigenetic Drift and Aging
Gaceta Médica de México 2025
Open access · CC-BY
Epigenetic clocks and aging
Experimental Gerontology 2020
Open access · OA
The crosstalk between cellular reprogramming and senescence in aging and regeneration
Société des Produits Nestlé (SPN) 2025
Open access · US-GOV
Evaluation of the Effect of Seasonality on Biological Age in Adults
bioRxiv (Cold Spring Harbor Laboratory) 2026
Preprint · CC-BY